Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma

Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or...

Blenrep (Belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

GSK announces extension of US Food and Drug Administration review period for Blenrep (Belantamab mafodotin-blmf)...

FDA grants FTD to DB-1310 for advanced or metastatic non-squamous NSCLC

IND approval for LM-350 “CDH17 ADC” from the US FDA